NCT03417336View on ClinicalTrials.gov

Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk

NARecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 24, 2018

Primary Completion Date

April 24, 2029

Study Completion Date

April 24, 2029

Conditions
To Evaluate the Rate of Digestive and Urinary Toxicity
Interventions
RADIATION

prostatic boost in brachytherapy with high dose rate (HDR)

prostatic boost in brachytherapy with high dose rate (HDR)

Trial Locations (2)

21000

RECRUITING

Centre Georges François Leclerc, Dijon

21079

RECRUITING

CGFL, Dijon

All Listed Sponsors
lead

Centre Georges Francois Leclerc

OTHER